Listen to interview with host Eric Michaels & guest Dr. Karine Kleinhaus discuss the following:
- Can you explain your company’s medical technology? How do you turn placenta cells into life-saving medicine?
- I understand these cells work to repair the body against a number of conditions, can you explain what areas will these cells help patients? I understand nuclear attacks are also on your list?
- I read that these cells called PLX-R18 cells are being looked at by the National Institute of Health? Why is the NIH interested?
- I understand that this work you are doing with the NIH may also lead into helping cancer patients later on, can you explain how that will work?
Karine Kleinhaus, M.D., M.P.H., is Divisional Vice President, North America at Pluristem Therapeutics. She has worked with multiple public and private biotechnology companies on both public and investor relations.
Prior to that, she was an Assistant Professor in the Departments of Obstetrics and Gynecology and Psychiatry at the NYU School of Medicine. At NYU, Dr. Kleinhaus conducted medical research funded under a multi-year NIH grant. She published more than 25 papers in leading peer-reviewed journals such as the Annals of the New York Academy of Science, American Journal of Medical Genetics, and the American Journal of Epidemiology. Before that Dr. Kleinhaus practiced obstetrics and then completed two fellowships at Columbia University.
Dr. Kleinhaus received her medical degree from Tel Aviv University, earned a Master of Public Health from Columbia’s Mailman School of Public Health, and a bachelor’s degree, cum laude, from Princeton University.